Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy

Journal of Pharmaceutical Sciences

Volumn 104, Issue 6, 2015, Pages 2018-2028

  Huo, Meirong ^a   Zhu, Qinnv ^a   Wu, Qu ^a   Yin, Tingjie ^a   Wang, Lei ^a   Yin, Lifang ^a   Zhou, Jianping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

cancer chemotherapy; peptide delivery; polymeric drugs; prodrugs; targeted drug delivery

Indexed keywords

ANTINEOPLASTIC AGENT; MACROGOL; OCTREOTIDE; OCTREOTIDE POLYETHENE GLYCOL PACLITAXEL; PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG; DRUG CARRIER; MACROGOL DERIVATIVE; MICELLE; SOMATOSTATIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CHEMICAL STRUCTURE; CIRCULAR DICHROISM; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INDUSTRY; DRUG SYNTHESIS; ENDOCYTOSIS; FLUORESCENCE; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; MICELLE; NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NEOPLASMS; OCTREOTIDE; PACLITAXEL; POLYETHYLENE GLYCOLS; PRODRUGS; RECEPTORS, SOMATOSTATIN;

EID: 84929191858     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24438     Document Type: Article

References (40)

1. de Weger VA, Beijnen JH, Schellens JH,. 2014. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel-A review. Anticancer Drugs 25 (5): 488-494.
2. Andoh T, Kitamura R, Fushimi H, Komatsu K, Shibahara N, Kuraishi Y,. 2014. Effects of goshajinkigan, hachimijiogan, and rokumigan on mechanical allodynia induced by paclitaxel in mice. J Tradit Complement Med 4 (4): 293-297.
3. Lehoczky O, Bagameri A, Udvary J, Pulay T,. 2001. Side-effects of paclitaxel therapy in ovarian cancer patents. Eur J Gynaecol Oncol 22 (1): 81-84.
4. Giang I, Boland EL, Poon GM,. 2014. Prodrug applications for targeted cancer therapy. AAPS J 16 (5): 899-913.
5. Qu D, Lin H, Zhang N, Xue J, Zhang C,. 2013. In vitro evaluation on novel modified chitosan for targeted antitumor drug delivery. Carbohydr Polym 92 (1): 545-554.
6. Ding Y, Chen W, Hu J, Du M, Yang D,. 2014. Polymerizable disulfide paclitaxel prodrug for controlled drug delivery. Mater Sci Eng C, Mater Biol Appl 44: 386-390.
7. Jun YJ, Min JH, Ji da E, Yoo JH, Kim JH, Lee HJ, Jeong B, Sohn YS,. 2008. A micellar prodrug of paclitaxel conjugated to cyclotriphosphazene. Bioorg Med Chem Lett 18 (24): 6410-6413.
8. Kakinoki A, Kaneo Y, Tanaka T, Hosokawa Y,. 2008. Synthesis and evaluation of water-soluble poly(vinyl alcohol)-paclitaxel conjugate as a macromolecular prodrug. Biol Pharm Bull 31 (5): 963-969.
9. Zou Y, Fu H, Ghosh S, Farquhar D, Klostergaard J,. 2004. Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin Cancer Res 10 (21): 7382-7391.
10. Makino A, Kimura S,. 2014. Solid tumor-targeting theranostic polymer nanoparticle in nuclear medicinal fields. Sci World J 2014: 424513.
11. Duarte S, Faneca H, Lima MC,. 2012. Folate-associated lipoplexes mediate efficient gene delivery and potent antitumoral activity in vitro and in vivo. Int J Pharm 423 (2): 365-377.
12. Nkepang G, Bio M, Rajaputra P, Awuah SG, You Y,. 2014. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor. Bioconjug Chem 25 (12): 2175-2188.
13. Aher N, Banerjee S, Bhansali S, Yadav R, Shidore M, Mhaske S, Chaudhari R, Asai S, Jalota-Badhwar A, Khandare J,. 2013. Poly(ethylene glycol) versus dendrimer prodrug conjugates: Influence of prodrug architecture in cellular uptake and transferrin mediated targeting. J Biomed Nanotechnol 9 (5): 776-789.
14. Zhou X, Wang H, Shi P, Meng AM,. 2014. Characterization of a fusion protein of RGD4C and the beta-lactamase variant for antibody-directed enzyme prodrug therapy. Onco Targets Ther 7: 535-541.
15. Lee MH, Kim JY, Han JH, Bhuniya S, Sessler JL, Kang C, Kim JS,. 2012. Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug. J Am Chem Soc 134 (30): 12668-12674.
16. Tong GJ, Hsiao SC, Carrico ZM, Francis MB,. 2009. Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J Am Chem Soc 131 (31): 11174-11178.
17. Mariniello B, Finco I, Sartorato P, Patalano A, Iacobone M, Guzzardo V, Fassina A, Mantero F,. 2011. Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells. J Endocrinol Invest 34 (6): e131-e138.
18. Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJ, Kwekkeboom DJ, de Jong M,. 2014. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: Focus on future developments. Clin Transl Imaging 2: 55-66.
19. Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D,. 2014. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs. Int J Nanomedicine 9: 1537-1557.
20. Di, Cianni A, Carotenuto A, Brancaccio D, Novellino E, Reubi JC, Beetschen K, Papini AM, Ginanneschi M,. 2010. Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem 53 (16): 6188-6197.
21. Marsh HM, Martin JK Jr., Kvols LK, Gracey DR, Warner MA, Warner ME, Moertel CG,. 1987. Carcinoid crisis during anesthesia: Successful treatment with a somatostatin analogue. Anesthesiology 66 (1): 89-91.
22. Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J,. 2013. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab 98 (11): E1730-E1739.
23. Hodolic M, Fettich J, Rubello D,. 2009. Influence of tumour size and uptake of 99mTc-octreotide on radio-guided surgery for neuroendocrine tumors. Minerva Endocrinol 34 (2): 89-96.
24. Spetz J, Dalmo J, Nilsson O, Wangberg B, Ahlman H, Forssell-Aronsson E,. 2012. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma-Tools for choice of radionuclide therapy. Hormone Metab Res 44 (5): 400-404.
25. Iwase Y, Maitani Y,. 2012. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts. Cancer Sci 103 (2): 310-316.
26. Xu W, Burke JF, Pilla S, Chen H, Jaskula-Sztul R, Gong S,. 2013. Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy. Nanoscale 5 (20): 9924-9933.
27. Vllasaliu D, Fowler R, Stolnik S,. 2014. PEGylated nanomedicines: Recent progress and remaining concerns. Expert Opin Drug Deliv 11 (1): 139-154.
28. Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A,. 2014. PEG-A versatile conjugating ligand for drugs and drug delivery systems. J Control Release 192: 67-81.
29. Vandana M, Sahoo SK,. 2010. Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials 31 (35): 9340-9356.
30. Maeda H,. 2014. Research spotlight: Emergence of EPR effect theory and development of clinical applications for cancer therapy. Ther Deliv 5 (6): 627-630.
31. Cavallaro G, Licciardi M, Caliceti P, Salmaso S, Giammona G,. 2004. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. Eur J Pharm Biopharm 58 (1): 151-159.
32. Li C, Yu DF, Newman RA, Cabral F, Stephens LC, Hunter N, Milas L, Wallace S,. 1998. Complete regression of well-established tumors using a novel water-soluble poly(l -glutamic acid)-paclitaxel conjugate. Cancer Res 58 (11): 2404-2409.
33. Nie S, Hsiao WL, Pan W, Yang Z,. 2011. Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: In vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomedicine 6: 151-166.
34. Huo M, Zou A, Yao C, Zhang Y, Zhou J, Wang J, Zhu Q, Li J, Zhang Q,. 2012. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials 33 (27): 6393-6407.
35. Morisco A, Accardo A, Gianolio E, Tesauro D, Benedetti E, Morelli G,. 2009. Micelles derivatized with octreotide as potential target-selective contrast agents in MRI. J Peptide Sci 15 (3): 242-250.
36. Xie W, Liu J, Qiu M, Yuan J, Xu A,. 2010. Design, synthesis and biological activity of cell-penetrating peptide-modified octreotide analogs. J Peptide Sci 16 (2): 105-109.
37. Greenfield NJ,. 2006. Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc 1 (6): 2876-2890.
38. Cavallaro G, Maniscalco L, Campisi M, Schillaci D, Giammona G,. 2007. Synthesis, characterization and in vitro cytotoxicity studies of a macromolecular conjugate of paclitaxel bearing oxytocin as targeting moiety. Eur J Pharm Biopharm 66 (2): 182-192.
39. Akinc A, Battaglia G,. 2013. Exploiting endocytosis for nanomedicines. Cold Spring Harbor Perspect Biol 5 (11): a016980.
40. Greish K,. 2010. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 624: 25-37.